KR930702296A - α-치환 트립토판 디펩토이드 유도체 - Google Patents
α-치환 트립토판 디펩토이드 유도체Info
- Publication number
- KR930702296A KR930702296A KR1019930700602A KR930700602A KR930702296A KR 930702296 A KR930702296 A KR 930702296A KR 1019930700602 A KR1019930700602 A KR 1019930700602A KR 930700602 A KR930700602 A KR 930700602A KR 930702296 A KR930702296 A KR 930702296A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- amino
- methyl
- effective amount
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 238000000034 method Methods 0.000 claims abstract 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 9
- 102100021022 Gastrin Human genes 0.000 claims abstract 2
- 108010052343 Gastrins Proteins 0.000 claims abstract 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims abstract 2
- 230000002496 gastric effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- -1 hydroxy, phenyl Chemical group 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 7
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 3
- 235000019789 appetite Nutrition 0.000 claims 3
- 230000027119 gastric acid secretion Effects 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- CSIWDVJRSDYWDS-UHFFFAOYSA-N amino 3-oxopropanoate Chemical compound NOC(=O)CC=O CSIWDVJRSDYWDS-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- ZTTWHZHBPDYSQB-LBPRGKRZSA-N (2s)-2-amino-3-(1h-indol-3-yl)-2-methylpropanoic acid Chemical class C1=CC=C2C(C[C@@](N)(C)C(O)=O)=CNC2=C1 ZTTWHZHBPDYSQB-LBPRGKRZSA-N 0.000 claims 1
- ZXDOJLXKYNWBMK-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1=CC=C2C(C=O)CCCC2=C1 ZXDOJLXKYNWBMK-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- QBSYGVKHEOYBFA-UHFFFAOYSA-N CCCCCCCCC(C)CC(CC1=CNC2=CC=CC=C21)(C(=O)NC3CCC4=CC=CC=C4C3N=[N+]=[N-])OC(=O)N Chemical compound CCCCCCCCC(C)CC(CC1=CNC2=CC=CC=C21)(C(=O)NC3CCC4=CC=CC=C4C3N=[N+]=[N-])OC(=O)N QBSYGVKHEOYBFA-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- ZTPIMGZNUMFPGQ-UHFFFAOYSA-N amino 4-oxobutanoate Chemical compound NOC(=O)CCC=O ZTPIMGZNUMFPGQ-UHFFFAOYSA-N 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 150000002497 iodine compounds Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229940051877 other opioids in atc Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 230000000049 anti-anxiety effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57629690A | 1990-08-31 | 1990-08-31 | |
| US576,296 | 1990-08-31 | ||
| US726,654 | 1991-07-12 | ||
| US07/726,654 US5244915A (en) | 1990-08-31 | 1991-07-12 | Amico acid derivatives cyclized at the c-terminal |
| PCT/US1991/006177 WO1992004322A1 (en) | 1990-08-31 | 1991-08-29 | Alpha-substituted tryptophane dipeptoid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930702296A true KR930702296A (ko) | 1993-09-08 |
Family
ID=27076919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930700602A Withdrawn KR930702296A (ko) | 1990-08-31 | 1991-08-29 | α-치환 트립토판 디펩토이드 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5244915A (https=) |
| EP (1) | EP0546123A1 (https=) |
| JP (1) | JPH06502850A (https=) |
| KR (1) | KR930702296A (https=) |
| AU (1) | AU658377B2 (https=) |
| CA (1) | CA2088996A1 (https=) |
| FI (1) | FI930878L (https=) |
| IE (1) | IE913078A1 (https=) |
| NZ (1) | NZ239612A (https=) |
| PT (1) | PT98828A (https=) |
| WO (1) | WO1992004322A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631281A (en) * | 1989-06-29 | 1997-05-20 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives |
| CA2088195A1 (en) * | 1990-08-31 | 1992-03-01 | David C. Horwell | Cholecystokinin antagonists, their preparation and therapeutic use |
| US5593967A (en) * | 1990-08-31 | 1997-01-14 | Warner-Lambert Company | Cholecystokinin antagonists, their preparation and therapeutic use |
| CA2110986A1 (en) * | 1991-07-12 | 1993-01-21 | Geoffrey Neil Woodruff | Cholecystokinin antagonists useful in the treatment of panic attacks |
| US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| FR2700540B1 (fr) * | 1993-01-15 | 1995-02-17 | Irj | alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique. |
| US7077822B1 (en) | 1994-02-09 | 2006-07-18 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
| US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
| WO1995024389A1 (en) * | 1994-03-10 | 1995-09-14 | Warner-Lambert Company | Indole derivatives as cck receptor antagonists |
| US5420353A (en) * | 1994-03-11 | 1995-05-30 | Merck & Co., Inc. | Regiospecific process to make cis-1-amino-2-alkanol from epoxide |
| JP2000506141A (ja) * | 1996-02-27 | 2000-05-23 | マリンクロッド・インコーポレイテッド | 標識化ｃｃｋ―ｂ受容体リガンドによるヒト悪性腫瘍の検出および位置特定 |
| US7253210B2 (en) * | 2002-10-15 | 2007-08-07 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
| WO2002026104A2 (en) * | 2000-09-27 | 2002-04-04 | Niazi Sarfaraz K | A combination of appetite controlling agents which create a synergy and produce a satiating result |
| US20060062864A1 (en) * | 2000-12-28 | 2006-03-23 | Mccleary Edward L | Weight loss composition and method |
| JP2007514661A (ja) * | 2003-11-25 | 2007-06-07 | マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー | ニーマンピック病のシャペロンに基づく治療方法 |
| KR20070004676A (ko) * | 2004-02-10 | 2007-01-09 | 얀센 파마슈티카 엔.브이. | 알파４ 인테그린의 길항제로서의 피리다지논 |
| US20050245534A1 (en) * | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US20050261302A1 (en) * | 2004-04-29 | 2005-11-24 | Hoff Ethan D | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application |
| US20100222316A1 (en) * | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7880001B2 (en) * | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US8415354B2 (en) * | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| JP5133702B2 (ja) | 2005-01-05 | 2013-01-30 | アボット・ラボラトリーズ | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬 |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| WO2006074244A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757151A (en) * | 1985-11-14 | 1988-07-12 | Warner-Lambert Company | 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl] |
| US4814463A (en) * | 1985-12-31 | 1989-03-21 | Biomeasure, Inc. | CCK antagonists |
| JPH0761992B2 (ja) * | 1987-02-06 | 1995-07-05 | 武田薬品工業株式会社 | 置換アミン誘導体 |
| US4888427A (en) * | 1987-04-07 | 1989-12-19 | University Of Florida | Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain |
| US4877785A (en) * | 1987-10-01 | 1989-10-31 | G. D. Searle & Co. | Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents |
| EP0442878A4 (en) * | 1988-04-05 | 1991-10-23 | Abbott Laboratories | Derivatives of tryptophan as cck antagonists |
| NZ234264A (en) * | 1989-06-29 | 1993-05-26 | Warner Lambert Co | N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions |
| FR2700540B1 (fr) * | 1993-01-15 | 1995-02-17 | Irj | alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique. |
-
1991
- 1991-07-12 US US07/726,654 patent/US5244915A/en not_active Expired - Lifetime
- 1991-08-29 KR KR1019930700602A patent/KR930702296A/ko not_active Withdrawn
- 1991-08-29 CA CA002088996A patent/CA2088996A1/en not_active Abandoned
- 1991-08-29 JP JP3518049A patent/JPH06502850A/ja active Pending
- 1991-08-29 EP EP91919909A patent/EP0546123A1/en not_active Ceased
- 1991-08-29 AU AU88661/91A patent/AU658377B2/en not_active Ceased
- 1991-08-29 FI FI930878A patent/FI930878L/fi unknown
- 1991-08-29 WO PCT/US1991/006177 patent/WO1992004322A1/en not_active Ceased
- 1991-08-30 IE IE307891A patent/IE913078A1/en unknown
- 1991-08-30 PT PT98828A patent/PT98828A/pt not_active Application Discontinuation
- 1991-08-30 NZ NZ239612A patent/NZ239612A/en unknown
-
1993
- 1993-04-20 US US08/049,721 patent/US5397788A/en not_active Expired - Fee Related
-
1994
- 1994-12-05 US US08/347,999 patent/US5523306A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FI930878A7 (fi) | 1993-04-16 |
| JPH06502850A (ja) | 1994-03-31 |
| FI930878A0 (fi) | 1993-02-26 |
| CA2088996A1 (en) | 1992-03-01 |
| FI930878L (fi) | 1993-04-16 |
| EP0546123A1 (en) | 1993-06-16 |
| US5523306A (en) | 1996-06-04 |
| US5397788A (en) | 1995-03-14 |
| EP0546123A4 (https=) | 1994-04-27 |
| PT98828A (pt) | 1992-07-31 |
| AU8866191A (en) | 1992-03-30 |
| WO1992004322A1 (en) | 1992-03-19 |
| NZ239612A (en) | 1994-02-25 |
| US5244915A (en) | 1993-09-14 |
| AU658377B2 (en) | 1995-04-13 |
| IE913078A1 (en) | 1992-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930702296A (ko) | α-치환 트립토판 디펩토이드 유도체 | |
| KR920702678A (ko) | N-치환 시클로알킬 및 폴리시클로알킬 α-치환 Trp-Phe- 및 펜에틸아민 유도체 | |
| OA09368A (fr) | "Nouveaux dérivés peptidiques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent". | |
| CA2011745A1 (en) | Dopamine receptor ligands and imaging agents | |
| NO175592C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner | |
| TNSN98141A1 (fr) | Derives 1,2,3, 4-tetrahydronapthalene substitues | |
| RU96107400A (ru) | Карбоциклические и гетероциклические конденсированные соединения хинолинкарбоновой кислоты, пригодные в качестве иммунодепрессантов | |
| EP0343900A3 (en) | Piperazine compounds | |
| RU95117068A (ru) | Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений | |
| JP7680053B2 (ja) | オピオイド受容体変調のための多環式アミン | |
| JPWO1994003424A1 (ja) | 脳内滞留性化合物およびその用途 | |
| CA2036905A1 (en) | Condensed thiazole compounds, their production and use | |
| OA09454A (fr) | Nouveaux dérivés peptidiques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
| JPH02289572A (ja) | エセロリンの炭酸エステル誘導体およびその製造方法 | |
| RU2002118700A (ru) | Замещенные производные норборниламина, способ их получения, их применение в качестве медикаментов или диагностических средств, а также содержащие их медикаменты | |
| EP0361791A3 (en) | Azacyclic derivatives useful as medicaments | |
| DE60009871T2 (de) | Medikamente, die derivate der phosphorigensäure als aktiven inhaltsstoff enthalten | |
| FI104071B1 (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi | |
| ZA909419B (en) | Thiopene derivatives,the process for the preparation thereof and the pharmaceutical compositions containing them | |
| JPWO2000050429A1 (ja) | リン酸誘導体を有効成分とする薬剤 | |
| KR930702332A (ko) | Cck 길항제용 프로드러그 | |
| RU93053036A (ru) | α,ω -ДИАРИЛАЛКАНОВЫЕ ПРОИЗВОДНЫЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННЫХ ПРОИЗВОДНЫХ | |
| DE69230446D1 (de) | (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| US5100912A (en) | Bis(benzylpyrrolidine) derivatives as dopamine agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930227 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |